Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Might β3-adrenergic receptor agonists be useful in disorders of glucose homeostasis?
Jeffrey S. Flier
Jeffrey S. Flier
Published March 23, 2020
Citation Information: J Clin Invest. 2020;130(5):2180-2182. https://doi.org/10.1172/JCI136476.
View: Text | PDF
Commentary Article has an altmetric score of 8

Might β3-adrenergic receptor agonists be useful in disorders of glucose homeostasis?

  • Text
  • PDF
Abstract

Brown and beige adipose tissues contain thermogenic fat cells that can be activated by β3-adrenergic receptor agonists. In rodents, such drugs both diminish obesity and improve glucose homeostasis. In this issue of the JCI, O’Mara et al. and Finlin and Memetimin et al. report that chronic administration of the approved β3 agonist mirabegron to human subjects was without effect on body weight or fat mass, but improved several measures of glucose homeostasis. Though the mechanisms mediating these metabolic effects are uncertain, the data suggest that β3 agonists could have therapeutic utility in disorders of glucose homeostasis.

Authors

Jeffrey S. Flier

×

Total citations by year

Year: 2024 2023 2022 2021 Total
Citations: 1 3 2 2 8
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (8)

Title and authors Publication Year
Brown adipose tissue activation via UCP1 accelerates cardiac metabolic remodeling and attenuates early hypertrophic and profibrotic signaling in the initial response to pathological stress.
Azariyas Challa, Pablo Vidal, Santosh Maurya, Chandan Maurya, Lisa Baer, Yang Wang, Natasha James, Parth Pardeshi, Matthew Fasano, Andrew Carley, Kristin Stanford, E. Lewandowski
The FASEB Journal 2024
HDAC11 inhibition triggers bimodal thermogenic pathways to circumvent adipocyte catecholamine resistance
Emma L. Robinson, Rushita Bagchi, Jennifer Major, Bryan Bergman, Jennifer L. Madsuda, Timothy A. McKinsey
Journal of Clinical Investigation 2023
HDAC11 inhibition triggers bimodal thermogenic pathways to circumvent adipocyte catecholamine resistance
Robinson EL, Bagchi RA, Major JL, Bergman BC, Madsuda JL, McKinsey TA
2023
Mirabegron, a Selective β3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug
Dąbrowska AM, Dudka J
Journal of Clinical Medicine 2023
Reversible lysine fatty acylation of an anchoring protein mediates adipocyte adrenergic signaling
R Bagchi, E Robinson, T Hu, J Cao, J Hong, C Tharp, H Qasim, K Gavin, J da Silva, J Major, B McConnell, E Seto, H Lin, T McKinsey
Proceedings of the National Academy of Sciences 2022
The evolving view of thermogenic fat and its implications in cancer and metabolic diseases.
Yin X, Chen Y, Ruze R, Xu R, Song J, Wang C, Xu Q
Signal Transduction and Targeted Therapy 2022
Pioglitazone does not synergize with mirabegron to increase beige fat or further improve glucose metabolism
Brian S. Finlin, Hasiyet Memetimin, Beibei Zhu, Amy L Confides, Hemendra J. Vekaria, Riham H. El Khouli, Zachary R. Johnson, Philip M. Westgate, Jianzhong Chen, Andrew J. Morris, Patrick G. Sullivan, Esther E Dupont-Versteegden, Philip A. Kern
JCI Insight 2021
Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy
A Angelidi, M Belanger, A Kokkinos, C Koliaki, C Mantzoros
Endocrine reviews 2021

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 14 X users
On 1 Facebook pages
17 readers on Mendeley
See more details